Microglia’s Dual Role in Neurodegeneration Intensifies Focus on Targeted Therapies
Table of Contents
BOSTON, MA – A growing body of research reveals a complex and frequently enough contradictory role for disease-associated microglia (DAM) in the progression of neurodegenerative diseases like Alzheimer’s and tauopathies, challenging the long-held view of microglia solely as beneficial immune cells. New studies are pinpointing specific microglial phenotypes and activation states,suggesting that manipulating these cells – rather than simply boosting their overall activity – may hold the key to effective treatments.
For decades, microglia where considered the brain’s primary immune defenders, clearing debris and fighting inflammation. However, accumulating evidence demonstrates that in neurodegenerative diseases, microglia undergo meaningful transformations, becoming “disease-associated” and exhibiting both protective and detrimental functions. This duality presents a major hurdle in therapeutic advancement, as broad activation of microglia can exacerbate pathology in certain contexts. Millions worldwide are affected by neurodegenerative diseases, and understanding the nuanced role of microglia is crucial for developing targeted therapies that can slow or halt disease progression. the latest research focuses on harnessing the protective functions of DAM while mitigating their potentially harmful effects, offering a new avenue for intervention.
The Shifting Landscape of Microglial Function
Microglia exist on a spectrum of activation states. Initially, they respond to neuronal damage by adopting an “alternative” phenotype, promoting tissue repair and clearing apoptotic cells. Jimenez et al. (2008) demonstrated this age-dependent shift in the PS1M146L/APP751SL mouse model of Alzheimer’s disease, observing a transition from an alternative to a “classic” inflammatory microglial phenotype wiht age. However, prolonged or excessive activation can led to chronic inflammation and neuronal dysfunction.
The emergence of the DAM phenotype, characterized by unique transcriptional signatures, has further elaborate the picture. Orre et al. (2014) provided a detailed transcriptome characterization of cortical astrocytes and microglia, laying the groundwork for identifying these distinct microglial states. DAMs are thought to cluster around amyloid plaques and neurofibrillary tangles, actively engulfing debris and potentially contributing to plaque compaction. However, their prolonged activation can also release pro-inflammatory cytokines, contributing to neuronal damage.
TREM2: A Key Regulator of Microglial Activity
Recent research has highlighted the role of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) in regulating microglial function and DAM activation. TREM2 is a receptor expressed on microglia that influences their survival, proliferation, and phagocytic activity. Loss-of-function mutations in TREM2 are associated with an increased risk of Alzheimer’s disease.
Several studies demonstrate that activating TREM2 can ameliorate disease pathology. Price et al. (2020) showed that therapeutic TREM2 activation reduced amyloid-beta deposition and improved cognition in the 5XFAD mouse model. Similarly,Schlepckow et al. (2020) developed a dual-function TREM2 antibody that enhanced protective microglial activities. Wang et al. (2020) found that anti-human TREM2 induced microglia proliferation and reduced pathology in an Alzheimer’s disease model. these findings suggest that modulating TREM2 signaling could be a promising therapeutic strategy.
The Impact of ApoE4 and Future Directions
The apolipoprotein E4 (ApoE4) allele is the strongest genetic risk factor for late-onset Alzheimer’s disease, and its influence extends to microglial function. Research indicates that ApoE4 exacerbates tau-mediated neurodegeneration, as demonstrated in a mouse model (E4 markedly exacerbates tau-mediated neurodegeneration, Nature, 2017). This suggests that ApoE4 may impair microglial function or promote a detrimental microglial phenotype.
New tools are being developed to further dissect the role of microglia in neurodegenerative diseases. Henningfield et al. (2024) recently generated an inducible destabilized-domain Cre mouse line specifically targeting disease-associated microglia, offering a powerful tool for studying microglial function in vivo.
Moving forward, research will focus on identifying specific molecular targets within microglia to selectively modulate their activity, promoting beneficial functions while minimizing harmful effects. The goal is to develop therapies that can harness the power of microglia to combat neurodegeneration without triggering detrimental inflammation.
